English
Deutsch
Français
Nederlands
Español
Reset. Heal. Grow.
Ibogaine Support Person Guide: What Sitters Actually Do
Someone you care about is about to take ibogaine. Maybe it's a partner trying to break a fifteen-year opioid dependency. Maybe a sibling who has tried everything else. Maybe a friend deep in the work of psychedelic healing for trauma that has stalked them for decades. And now they've asked you — specifically you — to be there. To sit with them. To be the calm, sober presence in the room. That's a lot to carry. And if you've spent the last week reading everything you can find about ibogaine, master plants, and addiction recovery, you've probably noticed something: there's a lot of testimonial out there, a lot of clinical material, but not much written for the person sitting in the chair next to the mattress. This is for you. Ibogaine is a long-acting psychedelic alkaloid derived from the root bark of the iboga shrub, native to West and Central Africa. Unlike ayahuasca or psilocybin, which usually run their course in four to eight hours, an ibogaine session can last twenty-four to thirty-six hours from dosing to the tail end of the afterglow. The first eight to twelve hours are the most intense — what practitioners often call the visionary phase. The body lies very still. The mind is very much not still. For people using ibogaine for addiction — which is most of them, frankly — there's also a physical dimension that makes it unlike other psychedelic medicines. It interrupts opioid withdrawal in a way nothing else does. Within an hour of dosing, someone who was dope-sick that morning often isn't anymore. That's the part the research keeps confirming, and it's the reason families fly halfway around the world to try it. None of that means it's easy to witness. Your person may not look like they're having a profound healing journey. They may look uncomfortable, nauseous, half-asleep, occasionally distressed. Knowing this in advance keeps you from panicking when it happens. The role of a support person — sometimes called a sitter, sometimes a trip companion — is not to guide the experience. That belongs to the facilitator or medical team. Your job is much smaller and much more important than that. You are the steady ground. Here's what that looks like in practice: What you're not doing: interpreting their visions, asking them what they're seeing, offering your own theories about what trauma they need to release, or trying to comfort them out of a difficult moment. Discomfort during an ibogaine experience is often where the work happens. Your job is to make the room safe enough that they can stay in it. Ibogaine carries real cardiac risks. It can prolong the QT interval, which in plain English means it can mess with heart rhythm. This is why any responsible retreat or clinic screens with an EKG, blood work, and a thorough medication review before dosing. Reputable providers will not give ibogaine to someone with certain heart conditions, electrolyte imbalances, or specific medication combinations. Period. As the support person, you should know what the medical team is monitoring and where they are. If you're at a clinic, they're usually one room away. If you're at a more ceremonial retreat, ask in advance about emergency protocols, oxygen, an AED, and how far the nearest hospital is. These are fair questions and any provider worth trusting will answer them without flinching. If anything feels off — your person's breathing changes, they become unresponsive in a way that seems different from the deep introspective stillness, their lips look blue, they vomit while lying flat — get medical staff in the room immediately. You're not being dramatic. You're doing your job. The week leading up to the session matters almost as much as the session itself. A few things worth doing: And a quiet one: if your person is going through this for addiction, know that ibogaine is not a cure. It's a window. The hard work of staying clean, building a different life, repairing relationships — that comes in the weeks and months afterward. Your steady presence then matters as much as it does during the dose. For the first hour or two, not much. They may feel a buzzing in the body, a slight unsteadiness, some nausea. Then the visionary phase comes on — closed-eye imagery, often described as cinematic, sometimes life-review, sometimes ancestral, sometimes deeply strange. Outwardly they'll look like they're sleeping with their eyes closed. Hours twelve to twenty-four are usually quieter visually but cognitively intense — what people describe as a kind of relentless self-examination. The body is exhausted but the mind won't sleep. This is when your steady, undemanding presence matters most. You don't need to fix anything. Just be there. By hour thirty or so, the body is wrung out and finally sleeps. The first real meal afterward is a small ceremony of its own. Don't expect deep conversations about what they saw — most people aren't ready to talk for days, sometimes weeks. Integration takes time. The week following ibogaine is fragile. People often describe a soft, almost porous quality to their perception. Old triggers feel quieter. Cravings, for those who came in with them, are frequently muted or absent. There's a window — and that window is also when relapse risk is highest if someone returns to old environments without support. If you're close to this person long-term, the most useful thing you can do is help them protect that window. That might mean staying with them for a few days. It might mean helping them get to integration appointments, find a therapist who understands psychedelic work, or simply not be alone in a quiet apartment with too much time. It also means listening without trying to interpret. They will say strange things. They will cry at unexpected moments. They will sometimes seem disoriented about what they want their life to look like now. That's the medicine still working. Not every ibogaine experience produces a breakthrough. Some people have what feels like a long, uncomfortable trip and not much else — at first. Others have profound experiences that fade if integration is neglected. A few have medical complications that require real intervention. Going in with realistic expectations protects everyone in the room, including you. If you've been asked to sit for someone, take it as a real responsibility but not a sacred performance. Show up. Stay present. Trust the medical team. Trust the medicine. Trust your person to do the work that only they can do. For readers preparing to support a loved one — or considering this path themselves — a range of vetted ibogaine and plant-medicine retreats can be explored on our marketplace here. Whatever you choose, choose with eyes open and good questions ready.
When Others Sense the Spirit of Ayahuasca: Stories from Beyond the Maloca
A friend of mine came home from a ten-day ayahuasca retreat in the Sacred Valley and, within an hour of walking through her front door, her cat refused to come near her. Not for a day. For almost three weeks. The same cat that used to sleep on her chest now flattened its ears every time she entered the room. Eventually things settled. But she still talks about it, six years later, with the same puzzled half-laugh. If you spend any time in plant-medicine circles, you hear stories like this constantly. Someone comes back from ceremony and their dog acts strange. A coworker says “you feel different” without being told anything. A partner wakes up at 3 a.m. crying from a dream they can't explain. The person who drank the brew didn't say a word — and yet something seems to have followed them home. What's actually going on here? Is it suggestion, projection, a sensitive nervous system reading subtle cues? Is it something the rationalist worldview hasn't got language for yet? I want to walk through what people actually report, what the indigenous frameworks say about it, and what to do if you're the one who came back from a retreat carrying — well, whatever it is you're carrying. Let's get specific, because vague spiritual talk helps nobody. The reports tend to cluster into a few recognisable shapes, and they show up across cultures and across decades of ayahuasca tourism. None of this is universal. Plenty of people come home from ceremony and nothing strange happens at all — the dog is fine, the partner is fine, the houseplants are fine, and the only weird thing is how badly you want to quit your job. But the cluster of reports is consistent enough that dismissing it entirely feels lazy. In the Shipibo, Asháninka, and broader Amazonian lineages, ayahuasca isn't conceptualised as a drug. It's a being. A teacher. A relationship. When curanderos talk about the brew they use words like madre — mother — and they describe her as having agency, preferences, and a presence that doesn't end when the ceremony does. From inside that framework, the question “can other people sense the spirit of ayahuasca on me?” isn't strange at all. Of course they can. You spent a week in deep contact with something the tradition treats as alive. Why would that contact evaporate the moment you board a plane home? The Shipibo concept of mariri — the spiritual force a healer carries — assumes that prolonged work with master plants leaves a residue on the person. Sensitive beings, including animals and children, are thought to perceive it directly. You don't have to buy the metaphysics to find the framework useful. Even the most committed materialist has to admit that something measurable changes in a person after intensive ceremony: nervous-system regulation shifts, default-mode network activity is altered for weeks, pheromonal output may change with stress and sleep patterns, micro-expressions soften. Animals and children read those signals far better than adult humans do. Whether the “spirit” is literal or a useful name for a constellation of subtle changes is, frankly, a question above my pay grade. Here's where I have to be honest: I don't know. Nobody really does. The research is thin to non-existent — there's no peer-reviewed study on whether cats can tell their owner did ayahuasca last week, and there probably never will be. What I can say is that suggestion clearly accounts for some of it. If you come home glowing and tell your partner you had a profound encounter with a jaguar spirit, and then your partner dreams about a jaguar that night, the parsimonious explanation is that you planted the seed. Brains are pattern-matching machines, and dreams are particularly suggestible. But suggestion can't account for all of it. Animals don't speak English. A toddler doesn't know mum just spent four nights drinking a sacrament in the jungle. When a dog who has lived with you for nine years suddenly refuses to make eye contact for forty-eight hours, something is registering, and it isn't a story you told. My working stance — and you're free to disagree — is that the body of a person who has been through intensive plant-medicine work is genuinely different for a while. Different scent profile, different breath rhythm, different micro-movements, different gaze. The mystery isn't whether something is being perceived. The mystery is what to call it. If you're researching a retreat and reading this kind of thing freaks you out a little — good. It should. Going to ceremony is not like booking a yoga weekend. You are signing up to be rearranged, and some of that rearrangement is visible to people who love you. Worth thinking about before you book. A few practical notes from people who've walked this road: One thing the retreat brochures rarely mention: ayahuasca and other master plants change relationships, not just individuals. The person who comes home is not exactly the person who left. Sometimes the partner is delighted. Sometimes the partner is unsettled. Sometimes a friendship that ran on a particular kind of cynicism doesn't survive the shift. People considering plant medicine for addiction, depression, or stuck patterns often focus on what they hope will change inside them. Fair enough. But the relational ripple is real, and it's worth naming before you go. The healing is rarely contained to the cup you drink from. This is also why the question of where you sit matters as much as whether you sit. A reputable retreat — one with experienced facilitators, real screening, and an actual integration arm — will prepare you for the re-entry. A weekend operation run by someone who learned the songs from a YouTube playlist will not. If something here speaks to you, the available ayahuasca and plant-medicine retreats can be browsed and booked on our marketplace here, and I'd encourage you to read each one's preparation and aftercare protocols carefully before committing. The cat, by the way, eventually went back to sleeping on my friend's chest. She thinks the medicine took about three weeks to settle. The cat hasn't said.
Ibogaine for Addiction Recovery: An Honest Guide for People Considering It
If you're reading this, you've probably already tried the usual stuff. Twelve-step meetings. Suboxone. Rehab. Maybe a few. Maybe more than a few. And somewhere along the way you stumbled across the word ibogaine — usually in a recovery forum at 2 a.m. — and now you're wondering whether this strange West African plant medicine could be the thing that finally works. Here's the thing. Ibogaine is real. The interruption of opioid withdrawal it produces is genuinely unlike anything else in modern medicine. People do walk out of clinics free of the physical grip of heroin, fentanyl, oxycodone, methadone — sometimes after a single dose. That part isn't hype. But ibogaine is also one of the most demanding psychedelics on the planet, and the way it's marketed online glosses over the parts that matter most for someone weighing whether to actually book a treatment. So let's talk about it like adults. Ibogaine is the principal alkaloid in the root bark of Tabernanthe iboga, a shrub native to Gabon and parts of Central Africa. For centuries it's been used by the Bwiti, an initiatory tradition where massive doses of the bark are taken to encounter ancestors, face the self, and mark a passage into adulthood. The Western version of this — the clinical ibogaine treatment — strips out most of the ritual and uses purified ibogaine HCl or a total alkaloid extract in a medical setting. What makes it interesting for addiction is a quirk of pharmacology. Ibogaine appears to reset opioid receptor sensitivity and dampen the cravings that drive relapse. It's also a long, intense psychedelic experience — usually 18 to 36 hours of visions, life review, and what people describe as watching their own story play back in unflinching detail. Most participants don't call it pleasant. They call it useful. This is the part people want a yes-or-no on, and the honest answer is: yes, often, but with conditions. Observational studies and clinical reports out of Mexico, New Zealand, and Brazil consistently find that a single ibogaine session can eliminate or dramatically reduce opioid withdrawal symptoms within hours. Follow-up data on long-term abstinence is messier — some people stay clean for years, some relapse within months, and the difference usually has very little to do with ibogaine itself and almost everything to do with what happens afterward. People who treat ibogaine as a magic bullet tend to relapse. People who treat it as a doorway — and then walk through it with serious aftercare, therapy, community, and lifestyle change — tend to do remarkably well. The medicine clears the runway. You still have to fly the plane. It's been studied or used for: Methadone is the trickiest of these. Long-acting opioids hold on to receptors stubbornly, and most reputable clinics will require you to switch to a short-acting opioid for several weeks before treatment. If a clinic tells you they can treat you straight off methadone with no taper — find a different clinic. Ibogaine has killed people. Not many, in the grand scheme, but enough that you need to take this seriously before booking anything. The main issue is cardiac. Ibogaine prolongs the QT interval on an EKG, which in the wrong heart can trigger a fatal arrhythmia. Almost every recorded death has involved one or more of the following: pre-existing heart conditions, electrolyte imbalances, recent opioid or stimulant use masking heart issues, or — most commonly — treatment in unsupervised settings without proper screening. A responsible ibogaine provider will require, at minimum: If any of those are missing, walk away. I'm not exaggerating. The difference between a safe ibogaine treatment and a dangerous one is almost entirely a matter of medical screening and monitoring. Beyond cardiac risk, expect ataxia (you won't be able to walk for most of a day), severe nausea, and a psychological experience that can dredge up trauma you've spent years avoiding. This is not a recreational substance and it is not for the curious. It's for people with a specific problem they've been unable to solve another way. This question comes up constantly, and the answer depends on what you're actually fighting. Ibogaine is the heavier hammer for physical opioid dependence. If you're currently using daily and the withdrawal itself is what's keeping you trapped, ibogaine's ability to interrupt that cycle is unmatched. Ayahuasca won't do that — it won't pull you through withdrawal, and most ayahuasca retreats will require you to be clean of opioids for weeks before arrival. Ayahuasca tends to shine for the layer underneath the addiction — the trauma, the unresolved grief, the patterns of self-punishment. People often come to ayahuasca after they've achieved abstinence and want to work on why they were using in the first place. Some recovery paths use both: ibogaine to break the physical hold, ayahuasca and other master plants over the following year to do the slower psychological work. Neither is better than the other. They do different jobs. A thoughtful integration therapist or a clinic that's honest about its limits will tell you which makes sense for your situation, and won't try to sell you the one they happen to offer. The legal landscape matters here. Ibogaine is a Schedule I substance in the United States, which is why almost all reputable treatment happens in Mexico, Costa Rica, the Netherlands, Portugal, Brazil, New Zealand, or South Africa — countries where it's either legal, unscheduled, or specifically permitted for medical use. When you're vetting a provider, the questions to actually ask are: A good clinic will answer all of these without flinching. A sketchy one will get defensive or vague. Trust your gut on the phone call. Expect to pay somewhere between $6,000 and $15,000 for a legitimate clinical program of five to ten days. Anything dramatically cheaper is cutting corners somewhere — usually on medical staff. Anything dramatically more expensive is selling you luxury that has nothing to do with treatment outcomes. I'll say it again because it's the single most important thing in this whole article. The ibogaine session itself is the easy part. Staying changed afterward is the hard part. What you do in the 6 to 12 months after treatment matters more than the treatment itself. That means a real therapist who understands psychedelic integration. A community of people who get it — recovery groups, integration circles, peer support. A plan for the cravings that may still show up around month three. A complete rebuild of the environment, relationships, and routines that fed the addiction in the first place. People who skip this part and go back to the same apartment, same friends, same triggers tend to relapse, even after the most profound ibogaine experience. The medicine opens a window. You have to actually climb through it. If you've read this far and ibogaine still feels like something you want to seriously explore, the next step isn't booking — it's a conversation. With your doctor about cardiac screening. With a therapist about whether your psychological foundation can hold the experience. With clinics about their protocols. For readers who want to keep researching, a curated selection of ibogaine and other plant-medicine retreats can be browsed on our marketplace here. Take your time with this one. The right decision, made carefully, can change everything. The wrong one, made in desperation, can cost a lot more than money.
When Ayahuasca Tells You to Stay: Reading Messages From the Medicine
Picture this. You drink the brew expecting clarity about your next move — a new city, a new partner, a new version of yourself — and instead the medicine puts a hand on your chest and says, gently but firmly, stay. Not just once. Three ceremonies in a row. Maybe five. Maybe across two different retreats with two different facilitators on two different continents. This happens more often than people talk about. Ayahuasca rarely hands out the answers we ordered. Anyone who has spent real time around plant medicine has either lived this or watched a friend live it — the message that refuses to budge, even when every part of the rational mind is begging for permission to leave a relationship, a job, a city, a story about who they are. So what do you do when the vine keeps telling you not to move on from something — or someone — you were sure you needed to leave behind? There's a common assumption among first-timers that ayahuasca is a kind of cosmic search engine. Ask a clear question, get a clear answer, ideally one that confirms what you already suspected. The reality is messier. People who've sat in many ceremonies will tell you the medicine often answers a different question than the one you asked — usually a more honest one. If you went in asking should I leave my marriage? and the brew kept showing you your own avoidance patterns, your unfinished grief about your father, the part of you that runs the second anything gets uncomfortable — that's not the medicine dodging the question. That's the medicine answering the question underneath the question. The one you didn't have the courage to ask out loud. This is part of why experienced facilitators talk less about ayahuasca guiding you and more about ayahuasca revealing you. The plant doesn't write the script. It turns the lights on in rooms you've been pretending not to notice. Here's the question that haunts most people in this situation: how do I know the difference between genuine plant-medicine guidance and my own fear dressed up in shamanic clothing? It's a fair question. Ayahuasca journeys are vivid, emotional, and easy to interpret through whatever lens you brought in with you. A few honest signals that point toward real guidance rather than projection: Fear, by contrast, is loud and circular. It uses your own voice. It tells you stories about catastrophe, abandonment, humiliation. Medicine messages, when they're real, tend to feel oddly impersonal — like someone reading you the weather forecast rather than shouting at you from across a room. That said, nobody — not your facilitator, not a shaman with forty years of experience, not the loudest voice in your integration circle — can tell you with total certainty which is which. You have to learn to listen, and that takes time. When the medicine tells someone not to move on from a person, a place, or a chapter of their life, it almost never means what the literal English words suggest. Ayahuasca speaks in image, feeling, and metaphor. "Don't move on" rarely translates to stay exactly as you are, doing exactly what you've been doing. From conversations across many ceremonies, here are some of the things it has been understood to mean: None of this is a command to stay in something genuinely harmful. The medicine isn't asking you to tolerate abuse, neglect, or addiction-driving environments. If anything, in those cases, ayahuasca tends to be unmistakable about getting out. "Don't move on" usually shows up in the murkier territory — the relationship that isn't bad, just unresolved; the city you keep almost leaving; the version of yourself you keep almost letting die. The hardest part of plant-medicine work isn't the ceremony itself. It's the months afterward, when you're back in your kitchen at 7am trying to figure out what to actually do with what you heard. Integration is where the real work lives, and it's where most people quietly lose the thread. If the medicine has told you not to move on from something, and that message has stayed consistent across sittings, a few practices tend to help: It's also worth sitting with the possibility that the message will change. Ayahuasca isn't issuing a life sentence. It's offering a current reading. A year from now, after you've actually done the work the medicine asked of you, the instruction may shift. Many people who were told to stay eventually receive a clear sense that they're free to go — and by then, leaving means something completely different than it would have at the start. Plant medicine is powerful but it isn't infallible, and neither is your interpretation of it. Trust the message most when it has these qualities: consistency across ceremonies, calm rather than urgency, specificity about your own behavior rather than someone else's, and an uncomfortable resonance with something you already half-knew. Be more skeptical when the message arrives once in a particularly intense moment, contradicts everything you've previously received, asks you to do something that would harm you or others, or comes loaded with grandiose language about destiny and soulmates. The medicine tends toward humility, not melodrama. And remember: a good facilitator, a thoughtful integration therapist, and your own body's slow wisdom are all part of how you make sense of this. Ayahuasca isn't meant to replace your judgment. It's meant to expand the field of what you can perceive, so your judgment has more to work with. For readers who want to take this further and find a setting where this kind of work is held carefully, a range of curated ayahuasca retreats can be browsed on our marketplace here. The decision about whether and where to sit is yours — but the medicine, as anyone who has worked with it knows, has a way of telling you when it's time.
Why Juneteenth Matters Beyond the Black Community: A Reflection
On June 19, 1865, Union troops rode into Galveston, Texas and announced that the people enslaved there were free. The Emancipation Proclamation had been signed two and a half years earlier. Word, somehow, hadn't traveled. That gap between a legal truth and a lived one is the heart of Juneteenth — and it's the reason the day still matters, far beyond the community that birthed the celebration. For more than a century and a half, Black families gathered every June 19 to mark the moment freedom finally arrived. In 2021, after decades of grassroots advocacy, Congress made it a federal holiday. The vote moved through both chambers faster than almost anyone expected — a striking contrast to the thirty-plus years it took to establish the Martin Luther King Jr. holiday. Things have shifted. Other things haven't. If you've spent any real time with contemplative practice — Buddhist, yogic, plant-medicine, anything serious — you've bumped into the same idea over and over. The whole project is liberation. Freedom from craving, freedom from fear, freedom from the patterns that keep us locked inside ourselves. The Buddha's teaching is, at its root, a teaching about how to stop suffering and help others do the same. So here's a fair question: why would anyone walking a path of liberation ignore a national holiday literally about people being freed from bondage? The honest answer is that we shouldn't. Juneteenth isn't a holiday that belongs only to Black Americans, any more than the Fourth of July belongs only to the founding generation. It's a marker of a particular kind of human liberation — concrete, hard-won, late in coming — and contemplatives of every background have a stake in it. There's a concept in Buddhist practice called mudita — sympathetic joy. It's the practice of taking genuine pleasure in someone else's freedom, someone else's good fortune, someone else's relief from pain. Juneteenth is a mudita holiday if there ever was one. You don't have to share an ancestry to share the joy. A quick refresher, because the history gets fuzzy fast. Chattel slavery in the United States was a system of legal ownership of human beings, passed down generationally, enforced by violence, and stitched into the economy of an entire region. The Emancipation Proclamation, signed in 1863, declared enslaved people in Confederate states free — but the proclamation only had teeth where Union forces could enforce it. Texas was the last holdout. June 19, 1865 is the day enforcement finally arrived in Galveston. Annual celebrations started that very next year. Cookouts, red drinks, music, prayer, stories passed down. The holiday has had different names — Jubilee Day, Emancipation Day, Freedom Day — and it survived through Jim Crow, through the civil rights era, through long stretches when mainstream America paid no attention at all. That endurance is part of what's worth honoring. If you're not Black and you're wondering whether Juneteenth is yours to observe, the answer from most Black communities I've spent time around is: yes, but with care. Show up. Listen more than you talk. Bring food if you're invited to a gathering. Read something you haven't read before. Sit with the discomfort of history without rushing to resolve it. A few small, sincere ways to mark the day: None of these are performative gestures if you mean them. The line between honoring and appropriating is usually drawn by intent, attention, and humility. Here's the part that gets glossed over in feel-good Juneteenth posts: legal freedom and lived freedom are not the same thing. They never have been. The Thirteenth Amendment outlawed slavery — except as punishment for a crime, a loophole that helped build the modern carceral state. Voter suppression is alive. Mass incarceration is alive. The fights over how American history gets taught in public schools are, in part, fights over whether the next generation will inherit the truth or a sanitized version of it. For anyone serious about the inner work — meditation, plant medicine, depth psychology, whatever your modality — there's a parallel here worth noticing. Personal liberation and collective liberation aren't separate projects. You can sit in ceremony all weekend and have profound experiences of unity, then walk out into a world where freedom is still unevenly distributed. The integration question isn't only “what did I learn about myself?” It's also “what am I now responsible for?” Plant-medicine traditions across the Americas have always understood this. The Indigenous and mestizo lineages that gave us ayahuasca, peyote, and psilocybin mushrooms practiced healing as a community act, not a private therapy session. The healer's job was to restore right relationship — with the body, with the land, with the people. Freedom for one was bound up with freedom for all. That's not a metaphor. It's the working theory. If you want a practice for the day itself, try this. Find ten or fifteen minutes of quiet. Sit comfortably. Bring to mind, as best you can, the specific historical fact of June 19, 1865 — soldiers reading the order aloud, people hearing for the first time that they were free. Let yourself feel whatever rises. Grief, gratitude, awkwardness, anger, relief, confusion. None of it is wrong. Then widen the circle. Bring to mind people still living under conditions that look a lot like un-freedom — incarcerated people, trafficked people, people trapped in addiction, people held inside their own trauma loops. Wish them, sincerely, the experience of release. Then bring to mind yourself, and the places you still feel bound. Wish yourself the same. That's it. No special equipment, no ceremony fee. Just a few minutes of honest attention to what liberation actually is, and who still needs it. A lot of people come to ayahuasca, psilocybin, and other plant medicines carrying personal pain — addiction, depression, the long shadows of childhood. The work is real. But the deeper the work goes, the harder it becomes to pretend that personal suffering is unrelated to the suffering around us. The medicines tend to dissolve that wall whether we want them to or not. Juneteenth is a useful reminder, on the calendar, that liberation has a history. People fought for it, died for it, waited two and a half years past the official decree for word to reach them. The freedoms we get to play with in a ceremonial space — the freedom to look inside, to sit with hard things, to imagine ourselves differently — exist on top of that history, not separate from it. If exploring that kind of inner liberation through plant medicine is something you've been quietly considering, a range of curated retreats across the Americas can be browsed on our marketplace here. Whatever you choose, mark the day. Eat something good. Call someone you love. Sit with the long, uneven, still-unfinished work of being free.
Craving More Stories?
Join our ShopAyahuascaRetreats newsletter for the latest updates on thrilling
destinations and inspirational tales, delivered straight to your inbox!
We value your privacy. Your email address will never be shared or published.
When Did Ayahuasca Become a Luxury Only the Rich Can Afford?
Somewhere between the first time a Western seeker stumbled into a Shipibo maloca in the early 2000s and right now, ayahuasca got expensive. Not slightly expensive. Five-figure-package, white-glove-airport-pickup, organic-chef-prepared, infinity-pool-overlooking-the-Sacred-Valley expensive. And if you've spent any time researching retreats lately, you've probably noticed the same thing I have: the people who arguably need this medicine the most — folks crawling out of addiction, grinding through depression, sitting on years of unprocessed trauma — often can't afford it. So what happened? When did the vine that grew wild behind a curandero's house become a luxury product with a waiting list and a wellness concierge? Let's get into it honestly, because the people quietly considering whether to book an ayahuasca retreat deserve a clear-eyed answer, not a brochure. For most of its known history, ayahuasca wasn't a product at all. It was a practice. Curanderos and ayahuasqueros across the Amazon basin — Shipibo, Shuar, Asháninka, mestizo lineages — worked with the brew as part of a broader healing tradition. People paid what they could. Sometimes that was a chicken, a sack of rice, a few soles, or nothing at all if they were sick and broke. The Western pilgrimage started small. In the 1990s and early 2000s a trickle of seekers, anthropologists, and recovering addicts found their way to Iquitos or Pucallpa, often by word of mouth, and sat in ceremonies that cost maybe twenty or thirty dollars a night, sometimes less. Plenty of those early arrangements were informal, occasionally chaotic, and not always safe — but they were accessible. Then came the documentaries. Then the celebrity ayahuasca confessions. Then the wave of articles about psychedelic healing for addiction and PTSD. Then the investors. Somewhere in that decade-long arc, the market figured out that wealthy, miserable Westerners would pay a lot to feel whole again. And like every wellness category before it — yoga, meditation, breathwork, ice baths — the prices climbed to meet what the top of the market would bear. Here's the uncomfortable breakdown. A week-long ayahuasca retreat in Peru or Costa Rica now commonly runs between three and seven thousand dollars, and the boutique end goes well past ten. That money is not, mostly, going to the medicine itself. The brew is cheap to make. The vine and chacruna leaf grow in the jungle. What you're paying for is roughly this: None of that is automatically bad. A safe, comfortable, well-run retreat with proper screening, a medical professional on call, and integration support genuinely costs more to operate than a hut in the jungle with one shaman and a kettle. The question is whether what you're paying maps to what you're getting — and whether the curanderos pouring the medicine are seeing a fair cut. Often they aren't. Short answer: yes, but you have to work harder for it, and you have to accept more risk. There's a whole tier of the ayahuasca world that doesn't show up in the top Google results because it doesn't run paid ads. Smaller centers near Iquitos, Tarapoto, and Pucallpa still offer week-long stays in the $500–$1,500 range. Some are excellent. Some are sketchy. The reputable ones tend to be Shipibo- or mestizo-run, with modest accommodations, simple food, and a focus on the work rather than the wallpaper. You find them through forums, word of mouth, and patient digging — not glossy landing pages. The trade-off is real. Cheaper retreats often have less rigorous medical screening, fewer English-speaking staff, no formal integration program, and less institutional accountability if something goes wrong. That doesn't make them dangerous by default — many have run safely for decades — but it does mean you carry more of the responsibility for vetting them yourself. A few practical avenues if cost is the wall standing between you and this work: If you're sitting at your laptop with a tab open to a $5,800 retreat in the Sacred Valley and another tab open to your bank account, here's what I'd actually say. Price is not a proxy for quality. I've sat in cheap ceremonies that were profoundly skillful and expensive ones that felt like spiritual Disneyland. What matters is the lineage and experience of whoever is pouring the medicine, the integrity of the screening process (a place that doesn't ask about your SSRIs or heart conditions is a red flag, regardless of cost), the ratio of facilitators to participants, and whether there's any real plan for what happens after you fly home. Integration is where the work actually lands, and it's often the first thing cut from budget retreats and the most overpriced thing at luxury ones. If you're considering plant medicine for addiction, severe depression, or trauma, the stakes of choosing well go up sharply. This isn't a wellness weekend — it's a serious intervention, and serious interventions deserve serious vetting. Talk to former participants. Ask uncomfortable questions. Read the bad reviews, not just the testimonials. If a retreat won't connect you with a recent attendee, that tells you something. And don't let the marketing convince you that the only legitimate way to meet this medicine is through a curated package with a sound-healing add-on. Some of the most transformative ceremonies in history happened in a dirt-floor hut with one shaman, one icaro, and one very scared seeker. The medicine doesn't care about your thread count. What does it mean that a healing tradition born among people with very little has become, in its most visible form, something mostly available to people with a lot? The honest answer is that it's a familiar story — yoga, mindfulness, indigenous foods, ceremonial cacao — and it doesn't have a clean ending. Some of the money flowing into the Amazon is genuinely helping communities. Some of it is just extraction in nicer clothes. The retreats that take this seriously are usually the ones willing to talk about it openly, fund reciprocity programs, pay their indigenous staff equitably, and not pretend the whole thing is just commerce. As a prospective participant, you have more leverage than you think. Ask retreats how much of their fee goes to the curanderos. Ask what they give back to the communities the medicine comes from. The answers will tell you a lot about who you're really handing your money — and your psyche — over to. If something in this piece is nudging you toward taking the next step, a range of carefully vetted ayahuasca retreats across price points can be browsed on our marketplace here. Take your time. The medicine isn't going anywhere, and the right container is worth waiting for.
Mary Oliver, Attention, and Why Poetry Still Matters in the Quiet Hours Before Ceremony
There's a poem that keeps turning up in retreat centers. You'll find it scrawled in the back of someone's journal at breakfast on day three. Taped to the wall of a maloca in the Sacred Valley. Read aloud, sometimes shakily, during an integration circle when nobody knows quite how to begin. It's Mary Oliver's The Summer Day, and the final line — what is it you plan to do with your one wild and precious life? — has a way of cutting through the noise that ceremony tends to leave behind. I want to talk about why this poem keeps showing up in the world of ayahuasca, psilocybin, and other plant medicines. Not because Oliver herself wrote about psychedelics — she didn't. But because what she's pointing at is the exact same territory the medicines crack open: the quality of attention you bring to being alive, and what you intend to do with the days you still have. If you haven't read it, the structure is simple. Oliver opens with a child's question — who made the world, who made the swan and the bear and this particular grasshopper eating sugar from her palm. She describes the insect in close, almost tender detail. Its complicated eyes. Its pale forearms. The way it washes its face before flying off. Then she shifts. She admits she doesn't know what a prayer is. But she does know how to pay attention, how to fall down in the grass, how to be idle and blessed. And then comes the closer: Doesn't everything die at last, and too soon? Tell me, what is it you plan to do with your one wild and precious life? That's the whole thing. Maybe twenty lines. Nothing fancy. And yet people carry it around with them for decades. Anyone who's sat in a serious ceremony — ayahuasca, San Pedro, psilocybin, ibogaine — knows the feeling of returning. You come back into your body and your kitchen and your job and your relationships, and something has shifted. Sometimes it's enormous. Sometimes it's small. But the shift almost always involves a sharper relationship to time. You suddenly notice you've been sleepwalking through your own life. The medicine pulled back a curtain, and now you can't quite un-see what was behind it. Oliver's poem does something similar, only without the brew. She's not asking a metaphysical question. She's asking a practical one. You're going to die. So am I. So is everyone. Given that — what do you actually plan to do? This is the same question the master plants ask. People who come to plant medicine for addiction recovery, depression, trauma, or just a sense of being stuck — they often describe the experience as a confrontation with this exact problem. Not the cosmic stuff. The specific, granular stuff. Are you going to keep drinking? Are you going to keep avoiding that conversation with your father? Are you going to keep waiting for permission to live the life you actually want? There's a line in the middle of the poem that I think gets undervalued. Oliver writes that she doesn't know what a prayer is, but she knows how to pay attention. She offers attention as the substitute for prayer — or maybe as prayer itself. This is worth sitting with if you're considering a retreat. Most facilitators I've spoken to, across traditions, will tell you that the medicine isn't really the medicine. The medicine is the attention you learn to bring. Ayahuasca, San Pedro, psilocybin — these are amplifiers. They turn the volume way up on whatever you're already paying attention to, whether that's an old grief, a buried memory, the texture of the wind moving through the leaves, or the quality of the silence between the icaros. The work, before and after, is learning how to keep that dial turned up when you're back in ordinary life. That's where the poem becomes practical. How to fall down in the grass, how to kneel down in the grass, how to be idle and blessed. These are training instructions, not just pretty phrases. If you're in the research phase — weighing whether to book, comparing centers, reading reviews and trying to figure out if any of this is actually for you — I'd suggest something modest. Print the poem. Carry it with you for a week. Read it once in the morning and once before bed. Don't analyze it. Just let the final question sit there. Here are a few things people often notice when they do this: None of this replaces the actual preparation work — the dietary restrictions, the medical screening, the conversations with facilitators about your history and intentions. But it gets you closer to the doorway. It softens you. I'll offer one caution. Oliver's poem is so quotable that it sometimes gets used as decoration — printed on tote bags, screen-printed onto candles, dropped into Instagram captions next to photos of someone doing yoga at sunset. There's nothing wrong with that, exactly. But it can hollow the words out. The same hollowing-out can happen with plant medicine. People come back from a ceremony with profound material, and within a month it's been reduced to a handful of catchphrases. I learned to surrender. I met my inner child. I am pure love. Fine. Maybe. But what did you actually do on Tuesday? Did you call the person you needed to call? Did you stop the thing that's been killing you? Did you start the thing you've been afraid to start? The poem and the medicine both lose their power when they get turned into slogans. The question Oliver poses isn't supposed to feel inspirational. It's supposed to feel slightly threatening. Like a friend who loves you enough to ask the question you've been avoiding. If you're reading this, there's a reasonable chance you're somewhere in the long, quiet process of considering a plant medicine retreat. You've watched the documentaries. You've read the trip reports. Maybe you've talked to one or two people who've done it. You're trying to figure out whether this is the right thing for you, or whether it's just another shiny object you're hoping will fix what's been broken for a long time. The poem can't answer that for you. Neither can I. But the question at the end of it — the one Oliver leaves hanging — is, I think, the right question to bring with you into any decision about psychedelic healing. Not will this fix me. Not will this make me happy. But: given that the time is finite, given that everything dies at last and too soon, what do you actually plan to do? If the answer involves stepping toward a retreat, do it with care. Choose facilitators who screen you properly, who don't promise outcomes, who take integration seriously. For readers who want to take this further, a range of vetted ayahuasca and plant-medicine retreats can be browsed on our marketplace here. And whatever you decide — go or don't go — keep the poem somewhere you'll see it. The grasshopper, the grass, the impossible last line. They have a way of staying useful.
LSD for Depression: What the First Positive Phase 3 Trial Actually Means
Something quietly historic happened in psychedelic medicine this week. A company called Definium Therapeutics announced positive topline results from a Phase 3 trial of an orally disintegrating LSD tablet for major depressive disorder. If you skimmed the headline and moved on, I don't blame you — drug-development news tends to read like tax law. But this one matters, and not just for biotech investors. It matters for anyone who has been quietly wondering whether psychedelics might one day be a legitimate option for the depression they've been carrying around for years. So let's slow down and unpack what actually happened, what it doesn't mean, and how it fits into the bigger conversation about psychedelics, plant medicine, and the long, weird road from underground ceremony to prescription pad. The short version: Definium ran a large, placebo-controlled trial of a synthetic LSD product — they're calling it DT120 — given as a dissolvable tablet to adults with major depressive disorder. The trial hit its primary endpoint, meaning the LSD group showed a statistically meaningful drop in depression scores compared to placebo. This is the first time a Phase 3 LSD trial has produced positive topline data. Ever. For context, Phase 3 is the big one. It's the trial regulators look at when deciding whether to approve a drug. Companies have spent decades and hundreds of millions of dollars getting psychedelic compounds — psilocybin, MDMA, ibogaine, and now LSD — through earlier-stage research. Many have stumbled at this exact gate. So when a Phase 3 reads out positive, the whole field pays attention. The trial reportedly showed strong antidepressant effects with what the company described as a manageable safety profile. We don't yet have the full peer-reviewed dataset — topline announcements are the corporate teaser, not the academic paper — but the headline number is enough to shift the conversation. LSD has a reputation problem. For most people over forty, the word still conjures Timothy Leary, bad trips at music festivals, and decades-old D.A.R.E. warnings. It's the psychedelic that got the most demonised in the 1960s and the one that has, until recently, been the slowest to claw its way back into respectable research. But pharmacologically, LSD is remarkable. It's potent in microgram doses, lasts a long time (eight to twelve hours in a clinical setting), and binds tightly to serotonin receptors in ways that researchers think may help the brain form new connections — the same mechanism increasingly studied as the basis for psychedelic-assisted treatment of depression, addiction, and trauma. The duration, oddly, is part of the appeal for some developers: a single dosing session, well-supported, may produce effects that linger for weeks or months. That's the bet Definium and others have been making. Rather than asking depressed patients to take a pill every day for the rest of their lives, the model is fewer sessions, deeper experiences, longer-lasting relief. Whether that bet pays off at scale is what the next few years will decide. One positive Phase 3 doesn't approve a drug. The FDA still has to review the full submission, the manufacturing has to pass muster, and the agency will want to see how this product would actually be administered in real-world clinics. Given the duration of an LSD experience, that's a non-trivial question — you can't exactly send someone home with a tab and a brochure. Still, the symbolic weight is enormous. Consider where the field has been: Against that backdrop, a clean Phase 3 readout for LSD is a real data point. It suggests that the broader scientific case for psychedelics as serious antidepressants — not lifestyle drugs, not party substances — is holding up under the most rigorous kind of scrutiny we have. Now the necessary cold water. A positive Phase 3 does not mean LSD will be at your local pharmacy next year. Even on an optimistic timeline, you're looking at a regulatory review process measured in years, not months. And approval, when and if it comes, would likely come with significant guardrails: dosing in a clinic, supervision by trained staff, screening for contraindications, integration sessions afterward. It also doesn't mean LSD is the right tool for everyone with depression. Psychedelics aren't a universal solvent. People with personal or family histories of psychotic disorders are generally excluded from these trials for good reason. Certain medications — particularly SSRIs and lithium — interact in complicated ways. Cardiovascular conditions matter. And the experience itself, however well-supported, is not gentle. Eight hours inside your own psyche is not a Tylenol. Most importantly, a successful pharmaceutical doesn't invalidate the older, ceremonial forms of psychedelic healing. Ayahuasca, San Pedro, psilocybin mushrooms in supported retreat settings, ibogaine in licensed clinics abroad — these traditions and practices have helped people for decades, sometimes centuries, without a pharmaceutical wrapper. They serve different needs, in different contexts, with different risk profiles. If you're reading this because you're depressed, or stuck in addiction, or working through trauma, and you've been wondering whether psychedelics might help — the honest answer is: probably not by waiting for an FDA-approved LSD tablet. That option, if it materialises, is years away and will likely be expensive and gated by insurance. So what's actually available right now? A few realistic paths: If you're considering the retreat route, the homework matters more than the destination. Ask about medical screening. Ask who the facilitators are and how long they've been doing this. Ask about integration support afterward (this is the part most amateur operations skip, and it's arguably the most important). Ask what happens if something goes sideways at three in the morning. A reputable retreat will answer all of that without flinching. What this week's news really signals is that the era of treating psychedelics as fringe is ending. Slowly, messily, with plenty of setbacks — but ending. Whether your interest is pharmaceutical (a clinic in Boston in 2029) or ceremonial (a maloca in the Peruvian Amazon next spring), the cultural and scientific space for these medicines is expanding. That's good news for people who've tried everything else and are still suffering. It's also a reason to be patient and discerning. The hype cycle around psychedelics is real, and where there's hype, there are bad actors. A genuine path through plant medicine or psychedelic-assisted treatment is rarely the loudest or flashiest one. For readers who want to take this further by exploring supported, in-person work with these medicines, a curated range of ayahuasca and psychedelic retreats can be browsed on our marketplace here. Whatever path you choose, take it seriously. The medicine will.
Psychedelic Policy in 2026: MDMA Trials, Australia's Access Rules, and What It Means for Retreat-Seekers
If you've been quietly researching a psychedelic retreat over the past year — maybe an ayahuasca journey for old trauma, or a psilocybin program to interrupt a depressive spiral — you've probably noticed the landscape moving fast. Laws are shifting. New trials are launching. Countries you wouldn't have guessed are quietly building legal access pathways. And it's getting hard to tell what actually matters for someone weighing a real decision. So here's a grounded look at where psychedelics, plant medicine, and addiction research stand right now in 2026 — and what the recent wave of policy and clinical news actually means if you're thinking about sitting in ceremony or booking a retreat. No hype. No prophecy. Just the stuff worth knowing. The story of the last twelve months isn't a single breakthrough. It's a slow drip of small, real-world shifts: a federal lobbying disclosure here, a new MDMA study there, a regulator quietly loosening eligibility somewhere else. Taken together, these moves are pulling psychedelic-assisted care a little further out of the underground and a little closer to mainstream mental health treatment. For someone considering a retreat, this matters in two ways. First, the legal and clinical conversation around psychedelics affects how seriously friends, family, and your own doctor will take your decision. Second, the research now coming out gives you better questions to ask any retreat or therapist — about screening, integration, dose, and what reasonable outcomes actually look like. None of this means a clinical psilocybin trial in Stockholm is the same thing as a five-night ayahuasca dieta in the Sacred Valley. They're not. But the science and the ceremonial worlds are no longer running on completely separate tracks, and the cross-pollination is informing both. Federal lobbying records from the first quarter of 2026 show what's been true for a couple of years now: psychedelic policy in the U.S. is being pushed forward, more than anything else, by advocates focused on veterans and treatment-resistant PTSD. That's not a coincidence. It's the cleanest political story available — people who served, came home wounded in ways the VA's standard toolkit hasn't fixed, and found something that helped. This pressure has translated into real movement. The Department of Veterans Affairs has continued rolling out MDMA-assisted therapy trials inside its own system — including a trial first announced at the tail end of 2024 that has now actually launched. The framing matters: when the VA studies a substance, even cautiously, it slowly normalizes the idea that psychedelics belong in a clinical conversation rather than a moral one. For retreat-seekers, the practical upshot is small but real. If you're a veteran, or work with veterans, the path to legal psychedelic-assisted care inside a clinical setting is genuinely getting wider. For everyone else, it remains mostly a matter of waiting for state programs, traveling to a legal jurisdiction, or pursuing ceremony through traditional or quasi-legal frameworks abroad. One of the more interesting research stories of the year is a study, funded in part by the State of Maryland and the nonprofit Reason for Hope, comparing group MDMA-assisted therapy against the more familiar one-on-one model for PTSD. The Sunstone Therapies team is running it. The question they're asking — does group work as well as individual? — has enormous implications for cost, access, and the shape of future legal programs. If you've ever sat in a circle at a retreat, none of this will feel novel. Group ceremony is the historical norm for ayahuasca, San Pedro, and most traditional plant-medicine practice. The clinical world is, in a sense, catching up to something the indigenous world figured out a long time ago: that healing in the company of others has its own particular power. Witness matters. So does the held container. Why does this study matter for you? Because if group-format psychedelic therapy proves comparably effective, the economics of legal access shift dramatically. A six-person psilocybin group is far more affordable than a six-hour solo session with two therapists. That changes what kinds of programs become possible. And it lends quiet validation to the group format many existing retreats already use. Australia became the first country to formally reclassify psilocybin and MDMA for prescribed therapeutic use back in 2023, but the rollout has been famously cautious — high cost, narrow eligibility, paperwork that scared off most candidates. This year, regulators have loosened several elements of that pathway, making it modestly easier for authorised psychiatrists to treat patients with treatment-resistant depression or PTSD using psilocybin or MDMA. Don't read this as Australia becoming a psychedelic free-for-all. It hasn't. The framework is still tightly medical, still expensive, and still requires you to fit a specific clinical profile. But it's becoming a useful reference point for how a regulated psychedelic-therapy system can evolve when policymakers actually try to build one rather than wait for the federal level to move. If you're an Australian reader specifically weighing your options, this is the moment to talk to a psychiatrist who works in the space — the bar to entry has come down, even if it's nowhere near low. If you're elsewhere, the Australian experiment is the closest thing we have to a real-world test of medicalized psychedelic care, and it's worth watching. Two studies are worth pulling out of the recent wave. A Swedish trial reported an antidepressant effect of psilocybin in patients with major depressive disorder — adding to a now-substantial body of evidence that a single high-dose session, paired with appropriate psychological support, can produce meaningful reductions in depression scores. Separately, follow-up data from the German EPIsoDE trial suggest the antidepressant response to psilocybin can be sustained over time, not just measured in the first few weeks. I want to be careful here. "Sustained" in a clinical context usually means months, not forever. Some participants relapse. Some don't respond at all. The research consistently shows that integration — the unglamorous work of making sense of what happened and changing what you do afterward — is what separates lasting benefit from a fascinating Tuesday afternoon. What this means practically for anyone considering a retreat: A new UK poll found broad public support for regulated psilocybin access for people with serious mental health conditions. This tracks with similar surveys across North America and parts of Europe — people are increasingly comfortable with the idea that psychedelics belong in the toolkit, even when their own governments aren't yet. This gap between public opinion and policy is, I'd argue, the most interesting feature of the current moment. It's why so many retreats exist in jurisdictional grey zones, why ceremonies continue to grow despite no federal legal framework in the U.S., and why so many people you'd never expect — schoolteachers, executives, retired nurses — are quietly researching plant medicine for addiction, depression, or simply for the feeling of being stuck. Here's the thing: news cycles about MDMA trials and Australian regulations can feel a long way from your actual question, which is probably some version of "should I do this, and where, and is it safe?" Let me try to bridge that. First, the policy momentum is real but slow. If you're suffering now and waiting for legal access in your home country, that wait might be years. Many people who choose ayahuasca, psilocybin, or ibogaine retreats abroad are making a clear-eyed calculation: the option exists, the research is increasingly supportive, and they're tired of waiting. Second, the clinical research is giving you a vocabulary for evaluating a retreat. Ask about screening. Ask about medical history intake. Ask about facilitator training and supervision ratios. Ask what happens if you have a difficult night — because difficult nights happen, and the quality of the response is what separates a sound retreat from a risky one. Third, the master plants — ayahuasca, San Pedro, iboga, tobacco in its ceremonial form — operate within traditions that long predate any clinical trial. The science is catching up to something old. If you go that route, take both seriously: the research-backed protocols for safety and the lineage that gives the ceremony its form. For readers ready to take the question from "should I?" to "where might I?", a curated range of ayahuasca and plant-medicine retreats can be browsed on our marketplace here. The most useful next step isn't necessarily booking — it's seeing what's actually out there and what specific programs offer, so the abstract decision becomes concrete. The psychedelic moment we're living through isn't going to peak and pass. It's restructuring how mental health, addiction recovery, and self-exploration are talked about. Whether you eventually sit in ceremony or simply keep reading and thinking, you're paying attention at the right time.
Where U.S. Psychedelic Laws Actually Stand in 2026: A State-by-State Read
If you're sitting on the fence about a psychedelic retreat — maybe an ayahuasca week in Peru, maybe an ibogaine program in Mexico, maybe something closer to home — the legal weather report matters more than most retreat-seekers realize. Where a substance sits on the law books shapes who gets to offer it, how much it costs, and whether the person pouring your cup has a real license or a flimsy disclaimer. So here's a plain-English read on where U.S. psychedelics policy stood as legislatures wound down their 2026 sessions. Out of 115 psychedelics-related bills tracked this year — 108 at the state level, 7 federal — seventeen distinct measures have been signed into law. Two were vetoed. Forty-four died quietly with their sessions. About fifty are still technically alive in legislatures that haven't gaveled out. More than a quarter of this year's signings happened in a single month: May. That's the headline. The story underneath it is more interesting. Psilocybin still leads the raw count of enacted bills, but most of those wins are trigger laws — technical rescheduling measures that flip a switch the moment the FDA approves a psilocybin-based medicine. They matter, but they're plumbing. They don't change much for someone considering a retreat next month. Ibogaine is the genuinely surprising story. Twenty-five ibogaine-focused bills were introduced across fourteen states this year. Six are now law. A seventh — New Hampshire's HB1772 — sits one vote from passage. If that lands, the success rate for ibogaine bills clears 25%, which is well above the rate for psychedelic bills as a whole. Why ibogaine, why now? Three reasons keep coming up in legislative testimony: For readers weighing ibogaine specifically — usually because nothing else has touched their addiction or depression — the practical takeaway is that the U.S. landscape is moving, but slowly. Most legitimate ibogaine treatment still happens in Mexico, Costa Rica, or Portugal. Domestic clinical access is years away from anything resembling routine. Rather than march through every bill number, here's the shape of the month in plain language. California saw movement on regulated-access frameworks that have been circulating for years now. The state keeps inching toward something — a therapist-supervised model, probably psilocybin-first — without quite getting there. If you're a Californian who's been waiting to do this work locally, the honest read is: keep waiting, or travel. Colorado, already the regulated-access pioneer with its Natural Medicine program, continued to refine the operational rules. The first licensed healing centers have been seating clients, prices are landing in the $1,500 to $3,000 range per session depending on the provider, and the early reports from facilitators are roughly what you'd expect: lots of demand, complicated insurance picture, real clinical results mixed in with the predictable growing pains. Connecticut, Hawaii, Illinois, and Massachusetts each moved bills in committee that focus on research and limited therapeutic access — slow, deliberate, no fireworks. Georgia and Louisiana saw ibogaine-specific measures advance, mostly framed around veteran access and opioid use disorder research. Michigan and Missouri had bills die in chamber, which is a polite way of saying the votes weren't there yet. Oklahoma and Tennessee both moved on the research-funding angle. North Carolina had a measure progress further than most observers expected. New Hampshire — small state, outsized influence on this issue — kept HB1772 alive heading into June. At the federal level, the seven bills tracked include the usual mix of veteran-access carve-outs, research authorizations, and rescheduling proposals. Nothing has passed. Nothing is close to passing. Federal reform in this space remains a turtle race. Three practical implications if you're researching plant medicine right now. First, legality is not the same as safety. A retreat operating in a country where ayahuasca is legal isn't automatically run by competent people. Conversely, an underground psilocybin sitter in a state where it's still Schedule I might be the most skilled facilitator in your region. Use the legal picture as one data point, not a verdict. Second, the U.S. patchwork is going to confuse you, and that's reasonable. Oregon and Colorado have regulated psilocybin access. Several cities (Denver, Oakland, Detroit, Seattle, Cambridge, Somerville, Washington D.C. by ballot) have decriminalized at the local level. Most other states treat psilocybin as a Schedule I controlled substance. Ayahuasca occupies a strange middle ground — the brew itself is Schedule I federally, but the UDV and Santo Daime churches won religious-use exemptions in the 2000s. Ibogaine remains Schedule I with no domestic legal pathway outside of narrow research contexts. Third, the offshore retreat economy isn't going anywhere. Peru, Costa Rica, Brazil, the Netherlands (for psilocybin truffles), Jamaica, and Mexico still host the vast majority of ceremonies that Americans attend. Policy reform at home will, over the next five to ten years, build a domestic alternative. It will not replace the traditional Amazonian retreat model, and it shouldn't — those are different rooms with different medicine. A few honest questions to put to any operation you're considering, with the policy backdrop in mind: None of this is meant to scare you off. People genuinely benefit from these experiences — that's why the policy reform is happening at all. It's meant to push you toward the questions that matter while the legal scaffolding around this work is still being built. Several legislatures haven't adjourned yet, which means the year-end tally will shift. Watch New Hampshire on ibogaine. Watch a handful of states with carryover sessions where psilocybin therapy bills are still technically alive. At the federal level, the most realistic near-term reform isn't broad rescheduling — it's targeted veteran-access language quietly attached to a defense authorization bill. That's how policy actually moves in Washington: through side doors. Internationally, Australia's prescribed-MDMA-and-psilocybin pathway continues to produce real-world data. Germany has begun psilocybin compassionate use for treatment-resistant depression. Canada's Special Access Program keeps approving individual cases. The global picture is moving faster than the U.S. picture, which is part of why the offshore retreat model remains the default for most Americans seeking this work. If you've been quietly researching plant medicine because something in your life isn't moving — a depression that hasn't lifted, an addiction the patches haven't touched, a layer of grief that's outlasted talk therapy — the legal news is mostly good. The doors are opening, even if slowly, and the underground is becoming less underground every year. For readers who want to take the next step, a range of curated ayahuasca, psilocybin, and ibogaine retreats can be browsed on our marketplace here. Take your time with the decision. The medicine will still be here when you're ready, and so will the law — probably a little friendlier than it was when you started reading.
Dreaming of a Psychedelic Retreat?
We have the best deals and offers from thousands of organizers all over the world! Get them into your mailbox every week!
We value your privacy. Your email address will never be shared or published.
